We are live on ! Find out more
ZDA

Zweig-DiMenna Associates Portfolio holdings

AUM $722M
1-Year Est. Return 97.69%
This Fund
S&P 500
This Quarter Est. Return
+15.89%
1 Year Est. Return
+97.69%
3 Year Est. Return
+317.96%
5 Year Est. Return
+499.45%
10 Year Est. Return
+3,067.75%
AUM
$1.34B
AUM Growth
+$347M
Cap. Flow
+$259M
Cap. Flow %
19.39%
Top 10 Hldgs %
42.27%
Holding
106
New
20
Increased
24
Reduced
18
Closed
17

Top Buys

Rank Stock Value
1
WGS icon
GeneDx Holdings
WGS
+$21.6M
2
ORCL icon
Oracle
ORCL
+$19.1M
3
APP icon
Applovin
APP
+$18.6M
4
IOT icon
Samsara
IOT
+$13.1M
5
FTAI icon
FTAI Aviation
FTAI
+$12.8M

Sector Composition

Rank Sector Weight
1 Technology 39.85%
2 Industrials 9.68%
3 Healthcare 8.73%
4 Communication Services 7.71%
5 Financials 6.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
S icon
101
SentinelOne
S
$7.34B
-160,000
Closed -$3.83M
SHOP icon
102
Shopify
SHOP
$195B
-7,400
Closed -$593K
TECK icon
103
Teck Resources
TECK
$32.6B
-143,800
Closed -$7.51M
XHB icon
104
State Street SPDR S&P Homebuilders ETF
XHB
$1.62B
-19,600
Closed -$2.44M
LB
105
LandBridge Co
LB
$2.1B
-50,000
Closed -$1.96M
XYZ
106
Block Inc
XYZ
$47.5B
-21,350
Closed -$1.43M

Similar funds

Zweig-DiMenna Associates's Q4 2024 Portfolio in Review

As of Q4 2024, Zweig-DiMenna Associates held 106 positions worth $1.34B, up 35% from $990M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Zweig-DiMenna Associates deployed $259M of net new capital in Q4 2024, opening 20 new positions and adding to 24 existing holdings. Its largest new stake was GeneDx Holdings: 309,500 shares worth $23.8M.

By sector, the portfolio is most concentrated in Technology at 40% of assets, down from 43% a quarter earlier, followed by Industrials and Healthcare.

On the sell side, the largest reduction was Eli Lilly, an estimated $13.9M trimmed.

  • Zweig-DiMenna Associates's largest Q4 2024 buy was GeneDx Holdings: 309,500 shares worth $23.8M.
  • Zweig-DiMenna Associates added most to Samsara in Q4 2024, an estimated $13.1M increase.
  • Zweig-DiMenna Associates's biggest Q4 2024 reduction was Eli Lilly, cutting an estimated $13.9M.
  • Zweig-DiMenna Associates fully exited Newmont in Q4 2024, selling an estimated $9.92M.
  • Zweig-DiMenna Associates's ten largest holdings make up 42% of its $1.34B portfolio in Q4 2024.
  • Zweig-DiMenna Associates opened 20 new positions and closed 17 in Q4 2024.
  • Zweig-DiMenna Associates's portfolio value rose 35% quarter-over-quarter to $1.34B.

Based on Zweig-DiMenna Associates's 13F filing for Q4 2024, filed 21 Jan 2025.